Fig. 3.

Disease free and overall survival in previously untreated patients with peripheral tumors deemed to be medically inoperable after being treated with Cyberknife SBRT. a The median progression-free survival was estimated to be 28.5 months (95 % CI: 15.8 months to not reached). The overall disease-free survival at 3 years was 37.5 % (95 % CI: 17.7- 57.4 %). b The overall survival at 3 years (36 months) was 62.4 % (95 % CI: 74.3-47.3 %). The median overall survival time was not reached